Melatonin decreases calcium levels in retinotectal axons of Xenopus laevis by indirect activation of group III metabotropic glutamate receptors.
Melatonin is a neuromodulator that binds to receptors in the retinotectal laminae of the amphibian optic tectum. The effect of melatonin on calcium dynamics in Xenopus retinotectal axons was investigated by imaging retinotectal axons labeled with the fluorescent indicator Fluo-4. Melatonin exerted an inhibitory influence on depolarization-evoked calcium increases, and the melatonin receptor antagonist 4-P-PDOT blocked this effect. Blockade of group III metabotropic receptors (mGluRs) counteracted the effect of melatonin on retinotectal axons. Application of the group II/group III mGluR antagonist MSPG or the group III-selective antagonist MSOP abolished the effect of melatonin. Conversely, this effect was not significantly affected by the group I mGluR antagonist LY367385 nor by EGLU or LY341495 at concentrations that specifically inhibit group II mGluRs. Furthermore, a higher concentration of LY341495 that affects group III mGluRs inhibited the effect of melatonin. The data therefore support the hypothesis that, in retinotectal axons, melatonin reduces cAMP levels, thereby relieving PKA-induced inhibition of group III mGluRs; the newly activated mGluRs in turn inhibit voltage-sensitive calcium channels, leading to a decrease in Ca2+ concentrations. The role of GABA(C) receptors in retinotectal responses was also evaluated. GABA(C) receptor antagonists did not block the effects of melatonin but instead were additive. Moreover, while other studies have shown that in Xenopus tectal cells, GABA(C) receptors mediate inhibition, in retinotectal axons, the opposite appears to occur since depolarization-evoked calcium rises in retinotectal axons were inhibited by GABA(C) receptor blockade. This result suggests that activation of GABA(C) receptors produces an increase in the synaptic excitability of retinotectal axon terminals.
Prada
Claudia
C
Neuroscience Program, State University of New York at Buffalo, Buffalo, NY 14214, USA.
Udin
Susan B
SB
D000814:Aniline Compounds / Q000378:metabolism; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001369:Axons / Q000187:drug effects* / Q000378:metabolism; D002118:Calcium / Q000378:metabolism*; D003952:Diagnostic Imaging / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D018756:GABA Antagonists / Q000494:pharmacology; D066298:In Vitro Techniques; D008550:Melatonin / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D008959:Models, Neurological; D010721:Phosphinic Acids / Q000494:pharmacology; D010852:Picrotoxin / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D018094:Receptors, Metabotropic Glutamate / Q000502:physiology*; D012165:Retinal Ganglion Cells / Q000187:drug effects*; D013477:Superior Colliculi / Q000166:cytology / Q000187:drug effects; D013764:Tetrahydronaphthalenes / Q000494:pharmacology; D014966:Xanthenes / Q000378:metabolism; D014982:Xenopus laevis
D000814:Aniline Compounds; D000975:Antioxidants; D002118:Calcium; D018691:Excitatory Amino Acid Antagonists; D018756:GABA Antagonists; D008550:Melatonin; D010721:Phosphinic Acids; D010852:Picrotoxin; D011189:Potassium Chloride; D011725:Pyridines; D018094:Receptors, Metabotropic Glutamate; D013764:Tetrahydronaphthalenes; D014966:Xanthenes; C101879:(1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid; C114459:4-phenyl-2-propionamidotetraline; C409648:Fluo 4; C102718:metabotropic glutamate receptor 3; C024100:6-chloromelatonin